

March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma: Metastatic Trials

Clinical Trial Number	Title	Phase	Sites
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	II/III	<p>Contact for all Sites: Contact: IDEAYA Clinical Trials; 650-534-3616; IDEAYAClinicalTrials@ideayabio.com Contact: Darrin Beaupre, MD, Ph.D; 650-443-6306; dbeaupre@ideayabio.com</p> <p>Honor Health (Scottsdale, AZ) recruiting Contact: Oncology Clinical Trials Nurse Navigator; 480-323-1791; clinicaltrials@honorhealth.com Contact: 833-354-6667</p> <p>Moores Cancer Center (La Jolla, CA) not yet recruiting Contact: Katie O’Neil, BA; 858-822-5354; croneil@health.ucsd.edu Contact: Jazelle Molina; 858-822-5354; jgmolina@health.ucsd.edu</p> <p>UCLA Medical Center (Los Angeles, CA) recruiting Contact: Adyel Annelus; 310-794-4955; aanelus@mednet.ucla.edu Contact: Elizabeth Seja; 310-794-6892; eseja@mednet.ucla.edu</p> <p>The Angeles Clinic and Research Institute (Los Angeles, CA) not yet recruiting Contact: Saba Mukarram; 310-231-2181; smukarram@theangelesclinic.org</p> <p>California Pacific Medical Center (San Francisco, CA) recruiting Contact: Denise Fortun; 415-600-1775; denise.fortun@sutterhealth.org Contact: CPMC Clinical Research Group; clinicalresearch@sutterhealth.org</p> <p>University of California San Francisco (San Francisco, CA) not yet recruiting Contact: Sonia Contreras Martinez, BSN; 415-514-6427; sonia.contrerasmartinez@ucsf.edu</p> <p>University of Colorado Cancer Center (Aurora, CO) not yet recruiting</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

		<p>SCRI at HealthONE (Denver, CO) <i>recruiting</i> Contact: SCRI Front Desk; 720-754-2610; cann.ddudenvergeneral@sarahcannon.com</p> <p>University of Miami Sylvester Comprehensive Cancer Center (Miami, FL) <i>recruiting</i> Contact: CRSCutaneous@miami.edu</p> <p>Moffitt Cancer Center (Tampa, FL) <i>not yet recruiting</i></p> <p>Northside Hospital Atlanta (Atlanta, GA) <i>recruiting</i> Contact: Central Research Department; 404-303-3355; clinicaltrials@northside.com</p> <p>University of Iowa (Iowa City, IA) <i>recruiting</i> Contact: Asad Javed, MD; 319-467-5156; asad-javed@uiowa.edu</p> <p>Massachusetts General Hospital (Boston, MA) <i>recruiting</i> Contact: Kamaneh Montazeri, MD; 617-724-4000; kmontazeri@mgh.harvard.edu</p> <p>Dana Farber Cancer Institute (Boston, MA) <i>recruiting</i> Contact: Rizwan Haq; 617-632-6168; rizwan_haq@dfci.harvard.edu Contact: Linnea Dreg; 617-632-6705; linneam_drew@dfci.harvard.edu</p> <p>The Cancer and Hematology Centers (Grand Rapids, MI) <i>recruiting</i> Contact: The Cancer and Hematology Centers; 616-954-5550; ClinicalTrials@chcwm.com Contact: Jessica Miller, RN; 616-954-5550 ext 1651; Jmiller@chcwm.com</p> <p>Mayo Clinic (Rochester, MN) <i>not yet recruiting</i></p> <p>Washington University School of Medicine (Saint Louis, MO) <i>not yet recruiting</i></p> <p>Roswell Park Cancer Institute (Buffalo, NY) <i>not yet recruiting</i></p>
--	--	---

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

		<p>Contact: Benjamin Switzer, DO; 716-845-7668; Benjamin.switzer@roswellpark.org Contact: Igor Puzanov, MD; 716-845-7505; igor.puzanov@roswellpark.org</p> <p>Northwell Health (Manhasset, NY) recruiting Contact: Richard Carvajal, MD; rcarvajal2northwell.edu Contact: Tracy Green, BS; tgreen22@northwell.edu</p> <p>Memorial Sloan Kettering Cancer Center (New York, NY) recruiting Contact: Alexander Shoushtari, MD; 646-888-4161; shoushta@mskcc.org Contact: James Smithy, MD; 929-623-0275; smithyj@mskcc.org</p> <p>Duke University Health System (Durham, NC) recruiting Contact: Carol Ann Wiggs, BSN; 919-684-0281; carolann.wiggs@duke.edu Contact: Emily Bolch; 919-668-6359; Emily.bolch@duke.edu</p> <p>University of Cincinnati (Cincinnati, OH) recruiting Contact: 513-584-7698; cancer@uchealth.com</p> <p>The Cleveland Clinic Foundation (Cleveland, OH) recruiting Contact: Lucy Kennedy, MD; 216-317-5561; kennedl5@ccf.org</p> <p>Thomas Jefferson University (Philadelphia, PA) recruiting Contact: Marlana Orloff, MD; 215-955-9980; marlana.orloff@jefferson.edu Contact: Kristie Hensel; 215-955-9980; kristie.hensel@jefferson.edu</p> <p>University of Pittsburgh Medical Center (Pittsburgh, PA) not yet recruiting Contact: Amy Rose, RN, BSN; 412-647-8587; kennaj@upmc.edu Contact: Jennifer Cleric, ND, RN; 412-864-7893; clericja@upmc.edu</p>
--	--	---

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>SCRI at Tennessee Oncology (Nashville, TN) <i>recruiting</i> Contact: SCRI Front Desk; 844-482-4812</p> <p>UT Southwestern Medical Center (Dallas, TX) <i>recruiting</i> Contact: Sanjay Chandrasekaran, MD; 833-722-6237; Sanjay.chandrasekaran@utsouthwestern.edu Contact: Desiree Pierre, BS; 214064803111; desiree.pierre@utsoutherwestern.edu</p> <p>Houston Methodist Cancer Center (Houston, TX) <i>not yet recruiting</i></p> <p>MD Anderson Cancer Center (Houston, TX) <i>recruiting</i> Contact: Sapna Patel, MD; 713-792-2921; sppatel@mdanderson.org</p>
NCT04728633	Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases	II	<p>Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, PA) <i>recruiting</i> Contact: Carin Gonsalves, MD; 215-955-6385; Carin.Gonsalves@jefferson.edu</p>
NCT03467516	Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma	II	<p>UPMC Hillman Cancer Center (Pittsburgh, PA) <i>recruiting</i> Udai Kammula, MD Contact: Josh Tobin, RN; 412-864-7754; tobinja@upmc.edu Contact: Allyson C Welsch, RN; 412-623-6763; welscha2@upmc.edu</p>
NCT05077280	A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma	II	<p>California Pacific Medical Center Research Institute (San Francisco, CA) <i>recruiting</i> Kevin B Kim, MD Contact: Madeline Decker; 415-600-3613; KimB@sutterhealth.org</p>
NCT05170334	Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma	II	<p>Moffitt Cancer Center (Tampa, FL) <i>recruiting</i> Ahmad Tarhini, MD, PhD Contact: Ahmad Tarhini, MD, PhD; 813-745-8581; ahmad.tarhini@moffitt.org Contact: Malik Hall; 813-745-5170; malik.hall@moffitt.org</p>
NCT05308901	Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint	II	<p>Providence Portland Medical Center (Portland, OR) <i>recruiting</i> Matthew Taylor, MD</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

	Inhibitor Naïve Metastatic Uveal Melanoma		Contact: Chris Fountain, RN; 503-215-2691; christopher.fountain@providence.org
NCT05524935	Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma	II	Moffitt Cancer Center (Tampa, FL) recruiting Nikhil I Khushalani, MD Contact: Malik Hall; 813-745-5170; Malik.Hall@moffitt.org
NCT06070012	Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma	II	UPMC Hillman Cancer Center (Pittsburgh, PA) not yet recruiting Diwakar Davar, MD, PhD Contact: Amy Rose, RN, BSN; 412-647-8587; kennaj@upmc.edu Contact: Samantha Berton, RN, BSN; bertonsf@upmc.edu
NCT06121180	Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma	II	Moffitt Cancer Center (Tampa, FL) recruiting Ahmad Tarhini, MD, PhD Contact: Malik Hall; 813-745-5170; Malik.Hall@moffitt.org
NCT03746431	A Phase 1/2 Study of [225Ac]-FPI-1434 Injection	I/II	Contact for all Sites: Contact: clinicaltrials@fusionpharma.com; +1 (888) 506-4215 City of Hope (Duarte, CA) recruiting Dana-Farber Cancer Institute (Boston, MA) recruiting Masonic Cancer Center, University of Minnesota (Minneapolis, MN) recruiting Memorial Sloan Kettering Cancer Center (New York, NY) recruiting Hospital of the University of Pennsylvania (Philadelphia, PA) recruiting University of Texas MD Anderson Cancer Center (Houston, TX) recruiting
NCT05415072	A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other	I/II	Contact for all Sites: Contact: Novartis Pharmaceuticals; 1-888-669-6682; +41613241111; novartis.email@novartis.com

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

	GNAQ/11 Mutant Melanomas		<p>Massachusetts General Hospital Hematology Oncology (Boston, MA) <i>recruiting</i> Contact: Ryan Sullivan; 617-724-5197</p> <p>Columbia University Medical Center- New York Presbyterian Onc Dept (New York, NY) <i>recruiting</i> Alexander Wei Contact: Caitlin Rogers; 212-885-0878; cr3311@cumc.columbia.edu</p> <p>Memorial Sloane Kettering Cancer Center MSKCC (New York, NY) <i>recruiting</i> Contact: Alexander Shoushtari; shoushta@mskcc.org</p>
NCT03947385	Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	I/II	<p>Contact for all Sites: <i>all sites recruiting</i> IDEAYA Clinical Trials; 650 534 3616; IDEAYAClinicalTrials@ideayabio.com</p> <p>UCLA Medical Center (Los Angeles, CA) Contact: Bartosz Chmielowski, MD; BChmielowski@mednet.ucla.edu</p> <p>San Francisco Oncology Associates (San Francisco, CA) Contact: clinicalresearch@sutterhealth.org</p> <p>Columbia University Medical Center - Herbert Irving Pavilion (New York, NY) Contact: Shaheer Khan, MD; sk4488@cumc.columbia.edu</p> <p>Duke University Medical Center (Durham, NC) Contact: Carol A Wiggs; cao13@duke.edu</p> <p>University of Cincinnati Cancer Center (Cincinnati, OH) Contact: 513-584-7698</p> <p>Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, PA) Contact: Marlana Orloff, MD; marlana.orloff@jefferson.edu</p> <p>The Sarah Cannon Research Institute/Tennessee Oncology (Nashville, TN) Contact: askSARAH; 844-482-4812</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>The University of Texas MD Anderson Cancer Center (Houston, TX) Contact: Jordi Ahnert, MD; jrodon@mdanderson.org</p>
<p>NCT03611868</p>	<p>A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors</p>	<p>I/II</p>	<p>Contact for all Sites: Contact: Angela Kaiser; 301-509-0357; angela.kaiser@ascentage.com</p> <p>University of Arizona Cancer Center (Tucson, AZ) recruiting Contact: Montaser Shaheen, MD; 520-626-5972; shaheenm@email.arizona.edu</p> <p>Highlands Oncology (Rogers, AR) recruiting Contact: Thad Beck, MD; 479-936-9900 Contact: Allie Pittman, MD; 479-695-4167; apittman@hgonc.com</p> <p>UCLA Hematology & Oncology Clinic (Los Angeles, CA) recruiting Bartosz Chemielowski, MD Contact: Rosleen Mala; 310-794-3879; RMala@mednet.ucla.edu</p> <p>Sarcoma Oncology Research Center (Santa Monica, CA) not yet recruiting Sant P Chawla, MD</p> <p>Children's National Research Institute (Washington, DC) recruiting AeRang Kim, MD, PhD Contact: Shari Walker; 202-476-2802; dvl@childrensnational.org</p> <p>Sarah Cannon/FCSRI (Fort Myers, FL) recruiting James Reeves, MD Contact: Joseph Morris; 845-661-4479; Joseph.Morris@FLCancer.com</p> <p>Washington University School of Medicine (Saint Louis, MO) recruiting Brian Van Tine, MD, PhD Contact: Michele Landeau; 314-747-9488; landeum@wustl.edu</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

		<p>Memorial Sloan Kettering (New York, NY) recruiting Contact: Sujana Movva, MD; zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org</p> <p>Duke Cancer Institute (Durham, NC) recruiting April Salama, MD Contact: Carol Ann Wiggs; 919-684-0281; carolann.wiggs@duke.edu</p> <p>Cleveland Clinic (Cleveland, OH) recruiting Brian Gastman, MD Contact: 866-223-8100</p> <p>Penn State Hershey Medical Center Cancer Institute (Hershey, PA) recruiting Joseph Drabick, MD Contact: Barbara Husic; 717-531-5471; bhusic@pennstatehealth.psu.edu</p> <p>Thomas Jefferson University Hospital (Philadelphia, PA) recruiting Marlana Orloff, MD Contact: Carolyn Palumbo; 215-955-9980; carolyn.palumbo@jefferson.edu</p> <p>Sarah Cannon Cancer Center (Nashville, TN) recruiting Meredith McKean, MD Contact: 844-482-4812</p> <p>University of Texas MD Anderson Cancer Center (Houston, TX) recruiting Neeta Somaiah, MD Contact: Gracy Zacharian; gzachari@mdanderson.org</p> <p>Next Oncology (San Antonio, TX) recruiting Contact: Anthony Tolcher, MD; 210-580-9500; atolcher@nextoncology.com</p> <p>Virginia Cancer Specialists (Fairfax, VA) recruiting Alexander Spira, MD Contact: Carrie Friedman; Carrie.Friedman@usoncology.com</p>
--	--	--

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

<p>NCT04130516</p>	<p>Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab</p>	<p>I/II</p>	<p>Contact for all Sites: <i>all sites recruiting</i> Contact: Tina Garyantes, PhD; (908) 420-1159; tgaryantes@linnaeustx.com Contact: Mackenzie Tseng-Lee, MBA; (513) 579-9911 ext 24120; m.tseng-lee@medpace.com</p> <p>Cedars-Sinai Medical Center (Los Angeles, CA) Contact: Kari Kayser, RN, BSN, CCRP; (310) 967-0694; kari.kayser@cshs.org</p> <p>Yale Cancer Center (New Haven, CT) Contact: Trisha Burrello, MS,CCRC; 203-464-5227; trisha.burrello@yale.edu Contact: Ingrid palma, MHS; 203-737-5342; ingrid.palma@yale.edu</p> <p>Massachusetts General Hospital (Boston, MA) Contact: Jessica Jiyeong Lin; jjlin1@partners.org</p> <p>University of New Mexico Comprehensive Cancer Center (Albuquerque, NM) Contact: Valerie Parks, RN, MSN; 505-925-0390; vparks@salud.unm.edu Contact: Carolyn Muller, MD; cmuller@salad.unm.edu</p> <p>Columbia University Herbert Irving Comprehensive Cancer Center (New York, NY) Contact: Samatha Petruzzelli, BS; 212-305-3236; sp4099@cumc.columbia.edu</p> <p>Memorial Sloan Kettering Cancer Center(New York, NY) Contact: Christopher Boutelle, BS; boutelc@mskcc.org</p> <p>University of Pennsylvania (Philadelphia, PA) Contact: Alexander Riccio; 215-829-6117; alexander.riccio@pennmedicine.upenn.edu Contact: Justine Cohen, MD; Justine.cohen@pennmedicine.upenn.edu</p> <p>Thomas Jefferson University, Sidney Kimmel Cancer Center (Philadelphia, PA) Contact: Dennis Stone, MS; 215-586-0199; askphase1@jefferson.edu</p>
--------------------	--	-------------	---

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>Contact: Traci Southwell, MSN, RN; Traci.Southwell@jefferson.edu</p> <p>MD Anderson Cancer Center (Houston, TX) Contact: Jordi Rodon, MD; 713-563-1930; jrodon@mdanderson.org</p> <p>The START Center for Cancer Care (San Antonio, TX) Contact: Isabel Jimenez, RN, MSN; 210-593-5265; isabel.jimenez@startsa.com</p>
NCT06022029	A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001)	I	<p>Contact for all Sites: Contact: Trials@OncoNanoMed.com; (682) 285-1411</p> <p>UPMC Hillman Cancer Center (Pittsburgh, PA) recruiting Liza Villaruz, MD Contact: Barb Stadterman; 412-647-5554; stadtermanbm@upmc.edu</p> <p>University of Texas Southwestern Medical Center (Dallas, TX) recruiting Contact: Heather McArthur, MD; 833-722-6237; canceranswerline@utsouthwestern.edu</p> <p>MD Anderson Cancer Center (Houston, TX) recruiting Sarina A. Piha-Paul, MD Contact: Hebah Elbahi; 832-294-7238; HMElbahy@mdanderson.org</p>
NCT03686124	ACTengine® IMA203/ IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)	I	<p>Contact for all Sites: Contact: Immatics US, Inc.; 346 204-5400; ctgoinquiries@immatics.com</p> <p>University of Miami Hospital and Clinics (Miami, FL) recruiting Contact: 305-243-2647; CRSCutaneous@miami.edu</p> <p>Columbia University Medical Center (New York, NY) recruiting Ran Reshef, MD Contact: 212-342-5162; cancerclinicaltrials@cumc.columbia.edu</p> <p>University of Pittsburgh Medical Center (Pittsburgh, PA) recruiting</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>Contact: Jason Luke, MD; 412-623-6132; lukej@upmc.edu</p> <p>University of Texas MD Anderson Cancer Center (Houston, TX) recruiting Contact: Dejka M Araujo, MD; 713-792-3626 daraujo@mdanderson.org</p>
NCT04109456	IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma	I	<p>Contact for all Sites: all sites recruiting Contact: Eddie Xing, Dr.; 949-520-0786; eddie.xing@inxmed.com</p> <p>Sylvester Comprehensive Cancer Center (Miami, FL) Contact: Lynn Feun, Dr.; 305-243-4981; lfeun@miami.edu</p> <p>Massachusetts General Hospital (Boston, MA) Contact: Ryan Sullivan, MD; 617-724-4000; rsullivan7@partners.org</p> <p>Dana-Farber Cancer Institute (Boston, MA) Contact: Rizwan Haq, PhD.; 617-632-5055; Rizwan_haq@dfci.harvard.edu</p> <p>Columbia University Medical Center (New York, NY) Contact: Richard Carvajal, Dr.; rdc2150@cumc.columbia.edu</p> <p>MD Anderson (Houston, TX) Contact: Sapna Patel; 713-792-2921 melanoma@mdanderson.org</p>
NCT05496686	Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma	I	<p>Contact for all sites: Contact: Mark L McLaughlin, PhD; 813-786-0033; mlm@modulationtherapeutics.com Contact: Karen E Hayes, PhD; 304-906-7692; karenh@modulationtherapeutics.com</p> <p>H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL) recruiting Nikhil I Khushalani, MD Contact: Leticia Tetteh, RN, BScN; 813-745-4617; Leticia.Tetteh@moffitt.org</p>
NCT04429542	Study of Safety and Tolerability of BCA101 Alone and in Combination with Pembrolizumab in	I	<p>Contact for all Sites: Contact: David Bohr, MS, MPH, MBA; 617-800-0335; info@bicara.com</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

	<p>Patients with EGFR-Driven Advanced Solid Tumors</p>	<p>Moore's Cancer Center UC San Diego Health (La Jolla, CA) <i>recruiting</i> Assuntina Sacco, MD Contact: Debanjali Ghosh; 858-246-0357; d1ghosh@health.ucsd.edu</p> <p>Keck School of Medicine of USC (Los Angeles, CA) <i>recruiting</i> Gino In, MD</p> <p>UCLA (Los Angeles, CA) <i>recruiting</i> Deborah Wong, MD</p> <p>H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) <i>recruiting</i> Jameel Muzaffar, MD Contact: Hamza Elmohd; 813-745-5554; Hamza.elmohd@moffitt.org</p> <p>Markey Cancer Center (Lexington, KY) <i>recruiting</i></p> <p>Dana Farber/Partners Cancer Care Inc (Boston, MA) <i>recruiting</i> Glen Hanna, MD Contact: DFCI Clinical Trials Hotline; 877-338-7425</p> <p>Memorial Sloan Kettering (New York, NY) <i>recruiting</i> Paul Paik, MD Contact: 646-608-3759</p> <p>Columbia University Herbert Irving Comprehensive Cancer Center (New York, NY) <i>recruiting</i> Contact: CPDM Nurse Navigator; 212-342-5162; cancerclinicaltrials@cumc.columbia.edu</p> <p>Cleveland Clinic (Cleveland, OH) <i>recruiting</i> Contact: 866-223-8100; TaussigResearch@ccf.org</p> <p>UPMC Hillman Cancer Center (Pittsburgh, PA) <i>recruiting</i> Dan Zanberg, MD Contact: Sarah Brodeur; brodeurs@upmc.edu</p> <p>Rhode Island Hospital (Providence, RI) <i>recruiting</i></p>
--	--	---

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>Medical University of South Carolina, Hollings Cancer Center (Charleston, SC) <i>recruiting</i> John Kaczmar, MD Contact: Lilli Neal; 843-792-8113; nealli@musc.edu Contact: Carly Fecio; 8437923479; fecio@musc.edu</p> <p>Vanderbilt University Medical Center (Nashville, TN) <i>recruiting</i> Mike Gibson, MD</p> <p>MD Anderson Cancer Center (Houston, TX) <i>recruiting</i> Van Morris, MD Contact: Beryl Tross; 713-745-0774; bmtross@mdanderson.org</p>
NCT05047536	KZR-261 in Subjects With Advanced Solid Malignancies	I	<p>Contact for all Sites: Clinical Operations; 650-822-5600; clinicaltrials@kezarbio.com</p> <p>Cedars Sinai Medical Center (Los Angeles, CA) <i>recruiting</i> Alain Mita, MD</p> <p>University of California Los Angeles (Los Angeles, CA) <i>recruiting</i> Bartosz Chmiekowski, MD, PhD</p> <p>Moffitt Cancer Center (Tampa, FL) <i>recruiting</i> Tiago Biachi de Castria, MD, PhD</p> <p>Winship Cancer Institute of Emory University (Atlanta, GA) <i>recruiting</i> R. Donald Harvey, Pharm D</p> <p>University Hospitals- Cleveland Medical Center (Cleveland, OH) <i>recruiting</i> Amit Mahipal, MD</p> <p>Fox Chase Cancer Center (Philadelphia, PA) <i>recruiting</i> Anthony Olszanski, MD</p> <p>Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville (Nashville, TN) <i>recruiting</i> Meredith McKean, MD</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>START (South Texas Accelerated Research Therapeutics) (San Antonio, TX) <i>recruiting</i> Kyriakos Papadopoulos, MD</p> <p>Virginia Cancer Specialists (VCS) (Fairfax, VA) <i>recruiting</i> Alexander Spira, MD</p>
NCT05075993	Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	I	<p>MD Anderson Cancer Center (Houston, TX) <i>recruiting</i> Contact: Siqing Fu, MD; 713-792-4318; siqingfu@mdanderson.org</p>
NCT05004025	Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma	I	<p>HonorHealth Research Institute (Scottsdale, AZ) <i>recruiting</i> Justin Moser, MD Contact: Clinical Trials Nurse Navigator; 833-354-6667; 480-323-1364; clinicaltrials@honorhealth.com</p> <p>The Angeles Clinic and Research Institute (Los Angeles, CA) <i>recruiting</i> Inderjit Mehmi, MD Contact: Saba Mukarram; 310-582-7900; smukarram@theangelesclinic.org</p>
NCT05169957	Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)	I	<p>University of Michigan Rogel Cancer Center (Ann Arbor, MI) <i>recruiting</i> Michael D. Green, MD, PhD Contact: Radiation Oncology; 734-936-4300; CancerAnswerLine@med.umich.edu</p>
NCT05628883	Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	I	<p>Moffitt Cancer Center (Tampa, FL) <i>recruiting</i> Amod Sarnaik, MD Contact: Yvonne Nguyen; 813-745-6869; yvonne.nguyen@moffitt.org</p>
NCT05607095	Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma	I	<p>Contact for all sites: Contact: Alexander Shoushtari, MD; 646-888-4161 Contact: Adam Schoenfeld, MD; 646-608-4042; schoenfa@mskcc.org</p> <p>Memorial Sloan Kettering Westchester (Harrison, NY) <i>recruiting</i></p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			Memorial Sloan Kettering Cancer Center (New York, NY) recruiting
NCT05341349	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases	I	Emory University Hospital/Winship Cancer Institute (Atlanta, GA) recruiting Mohammad K. Khan, MD, PhD Contact: Mohammad Khan, MD, PhD; 404-778-4126; m.k.khan@emory.edu Contact: Allyson K. Anderson; 404-686-0239; allyson.anderson@emory.edu
NCT05576077	A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING)	I	Contact for all sites: Contact: Megan Roberts; STARLINGTumorStudy@oncobay.com University of California Irvine (Irvine, CA) recruiting Contact: Ritesh Parajuli; 877-827-8839; ucstudy@uci.edu University of Miami (Miami, FL) recruiting Contact: Yandhira Figueroa; 305-243-5507; ytf2@med.miami.edu Contact: Lauren Miro; 305-243-4969; lem183@med.miami.edu Orlando Health (Orlando, FL) recruiting Sajeve Thomas, MD Contact: Adult Oncology Patient Referral; r-adultonctrialreferral@orlandohealth.com Moffitt Cancer Center (Tampa, FL) recruiting Dae Won Kim Contact: Yvonne Nguyen; 813-745-6869; yvonne.nguyen@moffitt.org Norton Cancer Institute (Louisville, KY) recruiting Jaspreet Grewal, MD Contact: NCI Research; 502-629-2500 ext 19460; earlyphase-nciresearch@nortonhealthcare.org Contact: 502-629-2500 Providence Healthcare Research Institute (Portland, OR) recruiting Matthew Taylor

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

		<p>Contact: Isa Ngirailmesang; 503-215-2714; Melissa.ngirailmesang@providence.org Contact: Patrick Rethwisch; Patrick.rethwisch@providence.org</p> <p>Allegheny Research Institute (Pittsburgh, PA) <i>recruiting</i> Yazan Samhour, MD Contact: Shelly Evans; 412-578-4905; Shelly.evans@ahn.org</p> <p>MD Anderson Cancer Center (Houston, TX) <i>recruiting</i> Contact: Serdar Gurses; 713-563-9710; sagurses@mdanderson.org Contact: Ashabari Sprenger; amukherjee1@mdanderson.org</p> <p>Medical College of Wisconsin (Milwaukee, WI) <i>not yet recruiting</i> Contact: Debra Pastorek; 414-805-6837; dpastore@mcw.edu</p>
NCT05655312	MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma	<p>Contact for all sites: Contact: Markus Puhlmann, MD; 319-665-2151; mpuhlmann@perspectivetherapeutics.com</p> <p>Yale University (New Haven, CT) <i>not yet recruiting</i> Contact: Mariam Aboian, MD, PhD; 203-785-5102</p> <p>University of Iowa (Iowa City, IA) <i>recruiting</i> Yusuf Menda, MD</p> <p>University of Kentucky (Lexington, KY) <i>recruiting</i> Ruta Arays, MD</p> <p>Mayo Clinic Rochester (Rochester, MN) <i>recruiting</i> Matthew Block, MD, PhD</p> <p>Saint Louis University (Saint Louis, MO) <i>recruiting</i> Medhat Osman, MD Contact: Martha Edwards, BSN, RN; 314-977-4498</p> <p>Washington University of St. Louis (Saint Louis, MO) <i>recruiting</i> Richard Wahl, MD Contact: 314-362-7100</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>University of Wisconsin (Madison, WI) recruiting Zachary Morris, MD, PhD Contact: Diana Trask; trask@humonc.wisc.edu</p>
NCT03941379	A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma	Observational	<p>Contact for all Sites: Medical Monitor; 617-500-8864; clinical@aurabiosciences.com</p> <p>Retina Associates SW, P.C. (Tucson, AZ) recruiting Cameron Javid, MD Contact: Amy Merz; amerz@retinatucson.com</p> <p>UCLA Jules Stein Eye Institute (Los Angeles, CA) recruiting Tara McCannel, MD Contact: Rosaleen Ostrick</p> <p>Stanford University (Palo Alto, CA) recruiting Prithi Mruthyunjaya, MD Contact: Mariana Nunez; 650-497-7846; mnunez1@stanford.edu</p> <p>Massachusetts Eye and Ear Infirmary (Boston, MA) recruiting Ivana Kim, MD Contact: Grayson Hanlon; 617-573-5627; Grayson_Hanlon@meei.harvard.edu</p> <p>Kellogg Eye Center (Ann Arbor, MI) recruiting Hakan Demirci, MD Contact: Pamela Campbell; 734-936-0138; pamtitus@med.umich.edu</p> <p>Associated Retinal Consultants (Royal Oak, MI) recruiting Antonio Capone Jr., MD Contact: Kendra Mellert; 248-288-9132 ext 1315; kmellert@arcpc.net</p> <p>Retina Center (Minneapolis, MN) recruiting Abdhis Bhavsar, MD Contact: Andi Gilchrist; 612-746-3880; agilchrist@retinadocs.com</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>Columbia University Medical Center (New York, NY) <i>recruiting</i> Brian Marr, MD Contact: Ellen Alt</p> <p>Oregon Health & Science University Casey Eye Institute (Portland, OR) <i>recruiting</i> Alison Skalet, MD Contact: Ann Lundquist; 503-494-6364; lundquia@ohsu.edu</p> <p>Wills Eye Hospital (Philadelphia, PA) <i>recruiting</i> Carol Shields, MD Contact: Lisa Flynn</p> <p>Retina Consultants of Carolina, PA (Greenville, SC) <i>recruiting</i> Contact: Lauren Frazier; 864-233-5722 ext 1107; lfrazier@retina-consultants.com</p> <p>St. Thomas Health/Tennessee Retina, PC (Nashville, TN) <i>recruiting</i> David Reichstein, MD Contact: Lisa Walden; 615-345-8912; lwalden@tnretina.com</p> <p>Retina Consultants of Houston (Houston, TX) <i>recruiting</i> Amy Scheffler, MD Contact: Allison Stroh</p> <p>Texas Retina Associates (Dallas, TX) <i>recruiting</i> Timothy Fuller, MD Contact: Sally Arceneaux; sarceneaux@texasretina.com</p> <p>University of Wisconsin (Madison, WI) <i>recruiting</i> Contact: Bonnie Verges</p>
NCT04588662	A Prospective Natural History Study in Uveal Melanoma	Observational	<p>Contact for all Sites: Principal Investigator: Shaheer A. Khan, MD Contact: Research Nurse Navigator; 212-342-5162; cancerclinicaltrials@cumc.columbia.edu</p> <p>Massachusetts General Hospital (Boston, MA) <i>not yet recruiting</i></p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

**March 2024 Currently Recruiting Clinical Trials for Patients with Uveal Melanoma:
Metastatic Trials**

			<p>Contact: Ryan Sullivan, MD</p> <p>Memorial Sloan Kettering Cancer Center (New York, NY) recruiting</p> <p>Contact: Alex Shoushtari, MD</p> <p>Thomas Jefferson University Hospital (Philadelphia, PA) recruiting</p> <p>Contact: Marlana Orloff, MD</p> <p>MD Anderson Cancer Center (Houston, TX) recruiting</p> <p>Contact: Sapna Patel, MD</p>
NCT04792463	Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	Observational	<p>Ohio State University Wexner Medical Center (Columbus, OH) recruiting</p> <p>Contact: Mohamed H Abdel-Rahman, MD, PhD; 614-292-1396; Mohamed.Abel-Rahman@osumc.edu</p> <p>Contact: Lindsey Byrne, MS, CGC; 614-293-3159; lindsey.byrne@osumc.edu</p>
NCT03809585	Observational Study of Iris Tumors	Observational	<p>Oregon Health & Science University (Portland, OR) recruiting</p> <p>David Huang, MD, PhD</p> <p>Contact: Denzil Romfh, OD; 503-494-4351; romfhd@ohsu.edu</p> <p>Contact: Humberto Martinez, COT; 503-494-7712; martinhu@ohsu.edu</p>
NCT03050268	Familial Investigations of Childhood Cancer Predisposition	Observational	<p>St. Jude Children's Research Hospital (Memphis, TN) recruiting</p> <p>Contact: Kim E. Nichols, MD; 866-278-5833; referralinfo@stjude.org</p> <p>Contact: Jamie L. Maciaszek, PhD; 866-278-5833; referralinfo@stjude.org</p>
NCT01931644	At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions	Observational	<p>Sanguine Biosciences (Los Angeles, CA) recruiting</p> <p>Houman Hemmati, MD</p> <p>Contact: Carolyn Bidwell; 855-836-4759; study@sanguinebio.com</p>
NCT06075589	Psychoeducation for Uveal Melanoma	Observational	<p>University of California Los Angeles (Los Angeles, CA) recruiting</p> <p>Contact: Megan Hoch; 310-794-6666; mhoch@mednet.ucla.edu</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2024 and only includes sites in the United States. This list is organized from latest phase to earliest phase: Phase III, Phase II, Phase I/II, Phase I, and Observational respectively, and includes only recruiting or not yet recruiting sites for active trials. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.